TABLE 2.
Inflammation |
Group A (observation) |
Group B (rabeprazole) |
Group C (hydrotalcite) |
Group D (combination) |
||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|
Pre | Post | P | Pre | Post | P | Pre | Post | P | Pre | Post | P | |
Endoscopic scores | ||||||||||||
Hyperemia | 2.25±0.74 | 2.18±0.81 | 0.053 | 2.13±0.87 | 2.15±0.79 | 0.083 | 2.20±0.85 | 2.16±0.77 | 0.069 | 2.18±0.69 | 2.00±0.80 | 0.102 |
Edema | 2.10±0.75 | 2.09±0.64 | 0.071 | 2.09±0.63 | 1.99±0.73 | 0.051 | 2.13±0.81 | 2.01±0.78 | 0.052 | 2.11±0.77 | 1.50±0.67 | 0.027* |
Histological scores | ||||||||||||
Chronic inflammation | 3.54±0.70 | 3.55±0.65 | 0.062 | 3.40±0.79 | 3.65±0.46 | 0.091 | 3.29±0.81 | 3.31±0.79 | 0.421 | 3.31±0.76 | 3.47±0.66 | 0.054 |
Activity | 2.90±0.72 | 2.57±0.85 | 0.077 | 2.95±0.68 | 2.76±0.91 | 0.060 | 2.45±0.54 | 2.50±0.47 | 0.051 | 2.87±0.72 | 1.97±0.78 | 0.029* |
Pre- and post-treatment data presented as mean ± SD. Scores of chronic inflammation and activity were graded on mononuclear cells and polymorphonuclear infiltration, respectively (0 = normal, 1 = mild, 2 = moderate and 3 = severe).
P<0.05 compared pre- and post-treatment in each group